Previous Article |
Table of Contents
| Next Article
Department of Pharmacology, University of Texas Southwestern
Medical Center, Dallas, TX 75390-9041
Communicated by Alfred G. Gilman, University of Texas
Southwestern Medical Center, Dallas, TX, February 6, 2002 (received for review December 15, 2001)
Individual subunits of protein phosphatase 2A (PP2A),
protein phosphatase 4, and protein phosphatase 5 were knocked out in Drosophila Schneider 2 cells by using RNA interference.
Ablation of either the scaffold (A) or catalytic (C) subunits of PP2A
caused the disappearance of all PP2A subunits. Treating cells with
double-stranded RNA targeting all four of the Drosophila
PP2A regulatory subunits caused the disappearance of both the A and C
subunits. The loss of PP2A subunits was associated with decreased
protein stability indicating that only the heterotrimeric forms of PP2A
are stable in intact cells. Ablation of total PP2A by using
double-stranded RNA against either the A or C subunit, or specific
ablation of the R2/B regulatory subunit, enhanced insulin-induced ERK
activation. These results indicated that the R2/B subunit targets
PP2A to the mitogen-activated protein (MAP) kinase cascade in Schneider 2 cells, where it acts as a negative regulator. A severe loss of
viability occurred in cells in which total PP2A or both isoforms of the
Drosophila R5/B56 subunit had been ablated. The
reduced viability of these cells correlated with the induction of
markers of apoptosis including membrane blebbing and
stimulation of caspase-3-like activity. These observations indicated
that PP2A has a powerful antiapoptotic activity that is
specifically mediated by the R5/B56 regulatory subunits. In contrast
to PP2A, ablation of protein phosphatase 4 caused only a slight
reduction in cell growth but had no effect on MAP kinase signaling or
apoptosis. Depletion of protein phosphatase 5 had no effects on
MAP kinase, cell growth, or apoptosis.
The protein
serine/threonine phosphatase 2A (PP2A) controls the phosphorylation
of numerous proteins involved in cell signaling and is an important
regulator of cell growth (1, 2). PP2A is the prototype of a subset of
PP2A-like phosphatases that includes PP4, PP5, and PP6. The PP2A
holoenzyme is a heterotrimer that consists of a core dimer, composed of
a scaffold (A) and a catalytic subunit (C) that associates with a
variety of regulatory subunits. Three families (R2/B, R3/PR72, and
R5/B56) of PP2A regulatory subunits have been characterized (1, 2).
The regulatory subunits have distinct properties and generate a
diversity of PP2A holoenzymes. A current model for regulation of PP2A
suggests that heterotrimers containing different regulatory subunits
have distinct functions in vivo. Only limited support exists
for this model. Genetic analysis has shown that the two regulatory
subunits of Saccharomyces cerevisiae direct PP2A to distinct
cellular functions (3). PP2A holoeznymes containing different
regulatory subunits also have distinct properties in vitro
(4). The functions of individual regulatory subunits in higher
eukaryotes are poorly understood.
One characterized function of PP2A is the regulation of
Ras-Raf-mitogen-activated protein (MAP) kinase signaling pathways. PP2A
has both positive and negative effects on these pathways that depend on
the cell type. PP2A can dephosphorylate and inactivate both MAP/ERK
kinase (MEK) and extracellular signal-regulated kinase (ERK) family
kinases in vitro (5-7). Treatment of cells with the
PP2A-selective inhibitor, okadaic acid, causes activation of both MEK
and ERK (8, 9). Incorporation of simian virus 40 small-tumor antigen
into PP2A complexes inhibits PP2A-mediated dephosphorylation of MEK and
ERK in vitro and causes activation of both kinases in intact
cells (10). Activation of MEK and ERK by simian virus 40 small-tumor
antigen correlates with loss of the R2/B subunit. These data all
suggest that PP2A is a negative regulator of MAP kinase signaling. PP2A
can associate with Raf, and PP2A-selective concentrations of okadaic
acid suppress Raf activation in a mammalian macrophage cell line (11).
Mutation of the R2/B subunit in Caenorhabditis
elegans causes a decrease in Ras-mediated vulval induction (12).
These later two observations suggest that PP2A can act as a positive
regulator of Raf activation. Within the Ras-mediated photoreceptor
development pathway in Drosophila, PP2A has a negative
effect upstream of Raf, but a positive effect downstream of Raf (13). A
strong possibility is that multiple actions of PP2A on MAP kinase
signaling are mediated by distinct holoenzymes.
Indirect evidence supports a role for PP2A in promoting cell survival
through inhibition of apoptosis. Treatment with okadaic acid
activates apoptosis in many cell types (14-20). Although these observations suggest PP2A plays a role in preventing apoptosis, they are not conclusive because other phosphatases, including PP1, PP4,
PP5, and PP6, are also inhibited by okadaic acid. PP2A associates with
several proteins involved in apoptosis including Bcl-2 (21,
22), caspase-3 (23), and the adenovirus E4orf4 protein (24-27).
Apoptosis induced by the adenovirus E4orf4 protein is
associated with PP2A isoforms containing the R2/B- and R5/B56 regulatory subunits. It is not known whether PP2A is directly involved
in other forms of apoptosis or if the antiapoptotic
activity is mediated by a particular regulatory subunit.
Double-stranded RNA (dsRNA)-mediated RNA interference (RNAi) has proven
to be a useful method for "knocking out" proteins expressed in
C. elegans and Drosophila melanogaster (28-32).
In contrast to mammals and yeast, Drosophila have a single
gene encoding each of the PP2A A (33), C (34), and R2/B subunits
(35), two genes encoding distinct isoforms of the R5/B56 subunit
homolog (36), and a single gene for a R3/PR72 homolog. The limited
number of phosphatase isoforms makes Drosophila an
attractive organism for PP2A gene knockout studies.
Drosophila also has a single gene encoding PP4 (37) and PP5
(38). We used RNAi to ablate PP2A, PP4, and PP5 from
Drosophila Schneider 2 (S2) cells to examine the roles of
these proteins in cellular signaling. We also used RNAi to ablate
individual PP2A regulatory subunits to test whether they have unique
functions. Ablation of individual PP2A subunits revealed a
mechanism controlling the assembly of PP2A oligomers by means of
protein stability. The data show that PP2A plays a negative role in
regulation of a MAP kinase pathway in S2 cells. Loss of PP2A also
caused apoptosis, demonstrating that this phosphatase is
crucial for cell survival. Consistent with the model in which regulatory subunits target PP2A to distinct functions, we show that
regulation of MAP kinase signaling and the antiapoptotic actions of PP2A are mediated by distinct regulatory subunits.
Production of Double-Stranded RNA.
Drosophila cDNA clones corresponding to PP2A subunits, PP4
and PP5, were purchased from Research Genetics (Birmingham, AL). The
cDNA clones were used as templates in PCR reactions where both the
sense and antisense primers contain a T7 polymerase binding site at the
5' end. A 700-bp region of the Drosophila PP2A R3/PR72 regulatory subunit was amplified by PCR from a 48-h embryo cDNA library
(kindly provided by Denis McKearin, University Texas Southwestern Medical Center). PCR products ( Cell Culture and dsRNA Treatment.
Serum-free medium adapted Schneider S2 cells (D.Mel-2) and
Drosophila serum-free medium were purchased from Life
Technologies (Rockville, MD). S2 cells were maintained in
Drosophila serum-free medium supplemented with 16.5 mM
L-glutamine and 46 µg/ml gentamicin at 28°C in
T-75 flasks. For dsRNA treatments, 1 ml of S2 cell suspension (1 × 106 cells/ml) in Drosophila expression
system expression medium (Invitrogen) was mixed with a final
concentration of 15 µg/ml of the specified dsRNA and plated in 35-mm
culture dishes. For cells that were treated with more than one dsRNA,
the final concentration of each dsRNA was 15 µg/ml. Cells were
incubated for 3 h at 28°C before adding 2 ml of
Drosophila serum-free medium. The dsRNA treatment was
performed for 3 days or as indicated in the figure legends.
Cell Extraction and Western Blotting.
The medium was aspirated, and cells were lysed for 10 min at 4°C in
RIPA buffer (20 mM Tris, pH 8.0/150 mM NaCl/1% Nonidet P-40/0.5% deoxycholate/0.1% SDS/0.2 mM sodium vanadate/10 mM
sodium fluoride/0.4 mM EDTA/10% glycerol). Lysates were clarified
by centrifugation at 15,000 rpm for 10 min in a microcentrifuge, and
samples were normalized according to protein concentrations determined
by the bicinchoninic acid protein assay (Pierce). Total protein
(30-60 µg) was resolved by SDS/PAGE, and individual proteins were
detected by Western blotting. The immunoblots were probed with 0.1%
F725 antiserum against the PP2A A subunit (4); 0.1% C-20 antiserum
against the PP2A C subunit (Affinity Bioreagents, Neshanic Station,
NJ); 0.1% M878 antiserum against the PP2A B56-1 subunit (4); 0.1%
PP5 antiserum (kindly provided by Michael Chinkers, University of South
Alabama, Mobile, AL) (39); 0.05% affinity-purified anti-PP4 c-int
polyclonal antibody (kindly provided by Brian Wadzinski, Vanderbilt
University, Nashville, TN) (40); 0.02% MAPK-YT monoclonal antibody
against activated ERK-1&2 (Sigma); or 0.01% polyclonal anti-ERK 1&2
(Sigma). A peptide corresponding to amino acids 409-423 of the
Drosophila R2/B subunit was sent to Capralogics (Hardwick,
MA) for production of the R2/B (409-423) rabbit polyclonal antibody,
which was used at 0.1% to probe immunoblots. Bound antibodies were
detected with the appropriate horseradish peroxidase-conjugated
secondary antibody and visualized by enhanced chemiluminescence.
Reverse Transcription (RT)-PCR.
The SUPERSCRIPT One-Step RT-PCR with PLATINUM Taq kit was
purchased from Invitrogen. S2 cells in 35-mm dishes were treated with
dsRNA for 72 h, and RT-PCR was performed as described by the
manufacturer. Primers used for RT-PCR were identical to those used to
make the PCR products used for dsRNA synthesis. Five microliters (1/10)
of the reaction was resolved on a 1% agarose gel.
Caspase Assays.
The ApoAlert Caspase-3 and Caspase-8 assay kits were purchased from
CLONTECH. S2 cells in 35-mm dishes were treated with dsRNA for 72 h, harvested, and assayed for caspase activity as described by the
manufacturer. Caspase-3-like and caspase-8-like activity were
determined by reading the absorbance at 405 nm in a 96-well plate
reader and adjusted for the protein concentration of each sample. The
results were normalized to the EGFP control sample. Values shown
represent the mean ± SE from four experiments.
Microscopy.
Cells were photographed by using phase-contrast optics at ×32
magnification with a Zeiss Axiovert 35 microscope and
ONCOR image software. Images were
imported into ADOBE PHOTOSHOP, and cell
number and the number of apoptotic (blebbing) cells were counted manually.
Selective Ablation of PP2A, PP4, and PP5 with RNAi.
Although studies with okadaic acid and other inhibitors have implicated
PP2A in multiple signaling pathways, it has been difficult to assign
specific functions to this phosphatase. Okadaic acid also inhibits PP1
at higher concentrations, and PP4, PP5, and PP6 are inhibited by the
same concentrations that block PP2A activity (41). To dissect the roles
of individual phosphatases in cellular signaling, we used RNAi to
delete selectively PP2A, PP4, and PP5 (42-44). Drosophila
S2 cells were treated with dsRNA targeted to individual PP2A subunits,
PP4, or PP5, and the effects on protein levels were determined by
Western blotting (Fig. 1A).
Treating cells with A- or C-subunit dsRNA for 72 h reduced the
corresponding subunits to barely detectable levels. Treatment with
either A- or C-subunit dsRNA alone caused a loss of all of the PP2A
subunits. Treatment with PP4 or PP5 dsRNA reduced the level of the
corresponding protein but had no effect on the levels of the other
phosphatase, or on PP2A. When cells were treated with individual dsRNA
targeting the R2/B, R3/PR72, R5/B56-1, or R5/B56-2 subunits,
each of the targeted proteins was ablated, but little effect was seen
on the other regulatory subunits. In general, ablation of individual regulatory subunits had little effect on the levels of the A and C
subunits. The exception was the R5/B56-1 and -2 double knockout where a significant decrease in the A and C subunits was observed. Ablation of all four regulatory subunits resulted in loss of the A and
C subunits. Treatment of S2 cells with a control dsRNA targeted to EGFP
had no effect on the levels of any PP2A subunits, PP4, or PP5.
Biochemistry
Actions of PP2A on the MAP kinase pathway and
apoptosis are mediated by distinct regulatory subunits
![]()
Abstract
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
![]()
Introduction
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
![]()
Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
500-700 bp) were cleaned in Microcon spin concentrators (Millipore) and resuspended at a final concentration of 200 ng/µl in sterile water. One microgram of each PCR product was
used to synthesize dsRNA with a large-scale T7 transcription kit from
Novagen. To anneal the single-stranded RNA, samples were incubated for
30 min at 65°C and cooled to room temperature. The pEGFP-C3 vector
(CLONTECH) was used as a template to produce a control dsRNA
corresponding to enhanced green fluorescent protein (EGFP).
![]()
Results and Discussion
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References

View larger version (46K):
[in a new window]
Fig. 1.
RNAi knockout of PP2A, PP4, and PP5 in Drosophila S2
cells. (A) Drosophila S2
cells were incubated in the presence of dsRNA corresponding to EGFP or
the phosphatase subunits indicated at the top. After 72 h, cells
were lysed in RIPA buffer containing 0.2 mM
Na2VO4 and 10 mM NaF2, and lysates
were clarified by centrifugation. Equal amounts of protein (30-60
µg) were separated on SDS-polyacrylamide gels, and detected by
Western blotting with antibodies against the proteins indicated on the
right. (B) Drosophila S2 cells were
incubated in the absence or presence of dsRNA corresponding to EGFP or
the phosphatase subunits indicated at the top. After 72 h, RT-PCR
was performed as described under Materials and Methods,
with primers against the phosphatase subunits indicated at the right.
Individual reactions (5 µl of the final reaction mixture) were
resolved on a 1% agarose gel and detected by staining with ethidium
bromide. Results shown are representative of three to seven
experiments.
Because antibodies against the Drosophila R5/B56-2 and R3/PR72 subunits were not available, the effectiveness of dsRNAs targeting these subunits was assessed by RT-PCR. Fig. 1B shows that treating S2 cells with R5/B56-2 and R3/PR72 dsRNA caused a significant reduction in the mRNA for these subunits. Treatment of cells with C-subunit dsRNA caused a complete loss of detectable C-subunit mRNA but had no effect on other PP2A subunit mRNAs. The loss of C-subunit mRNA in dsRNA-treated cells was consistent with the significant reduction in C-subunit protein levels (Fig. 1A). Treating cells with EGFP dsRNA had no effect on the level of PP2A subunit mRNAs.
The data in Fig. 1A showed that knocking out either the A or C subunits of PP2A caused the loss of all of the other PP2A subunits. To determine whether the loss of subunits in dsRNA-treated cells was caused by decreased stability, cells were treated with cycloheximide to block new protein synthesis, and the decay in the levels of PP2A subunits was monitored by Western blotting. The loss of proteins in dsRNA-treated S2 cells is usually maximal after 3 days (28; our observations). To examine protein stability, cells were treated with dsRNA for 48 h before addition of cycloheximide to ensure that protein levels had not dropped below the limit of detection. In control cells treated with EGFP dsRNA, the levels of A- and C-subunit protein were stable for up to 8 h after addition of cycloheximide (Fig. 2, EGFP). When cells were treated with A-subunit dsRNA a time-dependent decrease occurred in the levels of C-subunit and R5/B56-1 protein after cycloheximide addition. A time-dependent decrease in A subunit and R5/B56-1 protein also occurred when cells were treated with C-subunit dsRNA. The R2/B-subunit protein level decreased only modestly in cells treated with A- or C-subunit dsRNA for 48 h, and the loss of the R2/B subunit in the presence of cycloheximide was much slower than the other subunits, which suggested that the R2/B subunit was more stable than the A, C, or R5/B56-1 subunits. In cells treated with C-subunit dsRNA, a marked decrease occurred in the stability of the C-subunit protein. The reason for the rapid loss of C-subunit protein under these conditions is not clear. The levels of C-subunit present before cycloheximide addition are considerably lower in cells treated with C-subunit dsRNA. The level of C subunit may be close to the limit of detection by the antibody, and any further decrease would be magnified.
|
The data in Figs. 1 and 2 show that RNAi is an effective method for knocking out protein phosphatases in Drosophila S2 cells. The data provide new insights into mechanisms controlling the distribution of PP2A holoenzymes. In addition to potential autoregulation of the C subunit at the level of translation (45), our results suggest that PP2A is autoregulated at the posttranslational level to control the amounts of free subunits. The results in Figs. 1A and 2 are most consistent with a model in which individual PP2A subunits have low intrinsic stability. Assembly of the subunits into heterotrimeric complexes increases the stability of the individual proteins. Rapid degradation of free subunits may be a mechanism to protect the cell from deleterious effects of unregulated forms of PP2A. Attempts to overexpress the PP2A catalytic subunit in mammalian cells have been largely unsuccessful. Although this failure may be partly due to translational repression (45), our data argue that a major factor in limiting expression is rapid degradation of the free subunit. Depleting all four of the PP2A regulatory subunits led to loss of both the A and C subunit (Fig. 1A), which suggests that the AC dimer is unstable when not associated with one of the regulatory subunits. The presence of a pool of free AC dimers has been suggested by analysis of cell extracts (46, 47). In contrast, our data imply that little free dimer is present in vivo. Although a transient population of free AC dimer may exist, it seems unlikely that this form could accumulate to significant levels. The substantial amounts of AC dimer present in vitro may be generated during cell lysis by dissociation of PP2A holoenzymes.
PP2A Is a Negative Regulator of MAP Kinase Signaling in S2 Cells.
RNAi was used to examine the role of PP2A regulatory subunits in regulating MAP kinase activation in Drosophila S2 cells. Stimulation of the Drosophila insulin receptor activates MAP kinase in S2 cells in a Ras- and Raf-dependent manner (28, 48). Addition of insulin to untreated S2 cells resulted in a transient activation of MAP kinase activity that peaked at 5 min and returned to control values by 15 min (Fig. 3). Depletion of PP2A by using A- or C-subunit dsRNA caused enhanced activation of MAP kinase, especially at the 5- to 15-min time points (Fig. 3A). In contrast, depletion of PP4 or PP5 had little effect on insulin-stimulated MAP kinase activation (Fig. 3E). To test whether the actions of PP2A on MAP kinase signaling in S2 cells depended on a specific regulatory subunit, individual subunits were knocked out with RNAi. Loss of the R2/B subunit resulted in enhanced MAP kinase activation similar to that observed with the A- or C-subunit knockouts (Fig. 3B). In contrast, ablation of any of the other regulatory subunits had little effect on insulin-stimulated MAP kinase activation (Fig. 3 B-D).
|
Enhanced ERK activation in cells depleted of PP2A demonstrates that PP2A is a negative regulator of the MAP kinase pathway in Drosophila S2 cells. A role for PP2A in Drosophila Ras-mediated signaling pathways is consistent with previous studies on photoreceptor development (11). A predominant role of the Drosophila R2/B subunit in Ras-dependent signaling is supported by a study showing that decreased R2/B-subunit levels caused defects in photoreceptor development (49). PP2A can play both positive and negative roles in Ras-mediated signaling (11). Multiple actions of PP2A within the same pathway may be due to different PP2A holoenzymes acting at different steps. Although we cannot rule out a positive role for PP2A, our data indicate that the predominant action of PP2A in insulin-mediated MAP kinase activation in S2 cells is as a negative regulator. PP2A is also a negative regulator of MAP kinase signaling initiated by the epidermal growth factor receptor in mammalian CV-1 cells (8). Like S2 cells, the effects of PP2A in CV-1 cells seem to be mediated by the R2/B subunit.
Several potential targets for PP2A in insulin-stimulated pathways lead to ERK activation. Prolonged activation of ERK in PP2A- or R2/B-deficient cells could be caused by enhanced stimulation of upstream signals or a decreased rate of ERK dephosphorylation. PP2A dephosphorylates and inactivates ERK in vitro (50) and is responsible for the rapid phase of ERK inactivation (7). Insulin-dependent activation of ERK in S2 cells depends on the Drosophila MEK homolog DSOR1 (27), and PP2A also dephosphorylates and inactivates MEK in vitro (51). The effects of depleting PP2A are consistent with a role in the direct dephosphorylation of either MEK or ERK. The R2/B subunit acts as a positive regulator of Ras-mediated signal transduction in C. elegans. Genetic analysis suggests that R2/B acts downstream of Ras but upstream of Raf in the vulval induction pathway (12). PP2A can associate with Raf, and PP2A-selective concentrations of okadaic acid suppress Raf activation in a mammalian macrophage cell line (9). In contrast, PP2A acts as a negative regulator of Raf in Drosophila photoreceptor development (11). If Drosophila Raf is a target of PP2A, our data would indicate that it negatively regulates Raf activity. Finally, the effects of PP2A on ERK activation could be mediated by an alternative pathway. Simian virus 40 small-tumor antigen activates MEK in mammalian cells by pathways that use phosphatidylinositol-3-kinase and atypical isoforms of protein kinase C (52). A similar pathway may exist in S2 cells because insulin also stimulates phosphatidylinositol-3-kinase in S2 cells (27).
Loss of the R5/B56 Subunits of PP2A Induces Apoptosis.
We noted a striking decrease in S2 cell viability in some RNAi-treated cells. Treating cells for 3 days with A-, C-, or both R5/B56-subunit dsRNAs caused a 65-70% decrease in the number of cells (Fig. 4 A and B). RNAi depletion of PP5 had no effect on cell number, whereas depletion of PP4 reduced cell growth by 20%. One explanation for the dramatic decrease in the viability of dsRNA-treated cells was the induction of apoptosis. A common method to identify apoptotic S2 cells is the characteristic membrane blebbing that occurs in the later stages of apoptosis (53). In asynchronous cells undergoing active apoptosis, the characteristic features of membrane blebbing, DNA fragmentation, and chromosome condensation occur in about 15% of the population at any given time (54). Treating S2 cells with A- or C-subunit dsRNA caused membrane blebbing in 15-20% of the remaining cells (Fig. 4 A and C). No significant increases in blebbing cells were observed in S2 cells treated with the EGFP control dsRNA, or dsRNA corresponding to PP4 or PP5. The increase in the number of blebbing cells in PP2A-depleted cells was highly significant when compared with untreated or EGFP dsRNA-treated cells.
|
To provide further evidence that depletion of PP2A caused apoptosis, caspase activity was measured. S2 cells were treated with dsRNA targeting individual phosphatases and harvested 3 days later. Cell lysates were used to assay caspase activity by using a colorimetric assay that measures cleavage of p-nitroanaline from a peptide substrate specific for caspase-3. Control cells were also treated for 4 h with cycloheximide, a well characterized inducer of apoptosis. Depletion of PP2A with A- or C-subunit dsRNA caused a 2- to 3-fold increase in caspase-3-like activity (Fig. 4D). The level of caspase-3-like activity in PP2A-depleted cells was equivalent to that seen with cycloheximide treatment. In contrast, depletion of PP4 or PP5 did not cause a significant increase in caspase-3-like activity. When cell lysates were assayed with a caspase-8-specific substrate, any of the dsRNAs or cycloheximide had little effect on activity (data not shown).
Individual PP2A regulatory subunits were knocked out with RNAi to
determine which of the Drosophila subunits were involved in
the apoptotic response. Treating S2 cells for 3 days with dsRNA targeting the R2/B
, R5/B56-1, R5/B56-2, or R3/PR72
subunits had no effect on viability, membrane blebbing, or caspase
activity (Fig. 4 B-D). When both the R5/B56-1
and -2 subunits were knocked out with RNAi, cell number was decreased
and the percentage of blebbed cells increased to the same levels seen
in the A- and C-subunit knockouts (Fig. 4 B and
C). Caspase-3-like activity was increased to levels
comparable with PP2A-depleted or cyclocheximide-treated cells in
R5/B56 double-knockout cells (Fig. 4D). These results show
that the R5/B56 subunits, and not other PP2A regulatory subunits, have a specific function in preventing apoptosis. The results also show that the antiapoptotic function of R5/B56-1 and
R5/B56-2 are redundant, because the presence of either subunit alone
is sufficient to prevent apoptosis.
The activity of serine/threonine phosphatase inhibitors as potent inducers of apoptosis has been documented in a variety of cell types (20, 55, 56). Because the serine/threonine phosphatase inhibitors that cause apoptosis act on both PP1- and PP2A-like enzymes, it has been difficult to determine which phosphatase is involved. Although other phosphatases may play a role, our data show that depletion of a single family of PP2A regulatory subunits in S2 cells is sufficient to induce apoptosis. This result implies that PP2A activity is critical for cell survival and suggests that the apoptotic actions of serine/threonine phosphatase inhibitors are due to inhibition of PP2A. The rapid induction of apoptosis in mammalian cells by serine/threonine phosphatase inhibitors is associated with increased protein phosphorylation and depends on activation of caspase-3 (55). Apoptosis induced by dsRNA knockout of PP2A correlated with activation of protease activity toward a caspase-3 substrate peptide. Drosophila contains three caspases (DRICE, DCP-1, and DECAY) that are highly homologous to mammalian caspase-3 (57). Each of these fly caspases cleaves caspase-3 substrates. Although our assays cannot distinguish between these enzymes, the essential role of DRICE in S2 cell apoptosis (58) suggests that loss of PP2A, or of its R5/B56 subunits, leads to activation of DRICE. These results establish a critical role for PP2A in cell survival. Additional studies are needed to determine the signaling pathways and components of the apoptotic machinery that are targeted by R5/B56-containing forms of PP2A.
| |
Acknowledgements |
|---|
We thank Michael White and John Abrams for helpful discussions and critical review of this manuscript. This work was supported by Grant GM49505 from the National Institutes of Health (to M.C.M.). A.M.S. is a recipient of National Research Service Award GM20530 from the National Institutes of Health.
| |
Abbreviations |
|---|
PP2A, protein phosphatase 2A; dsRNA, double-stranded RNA; RNAi, RNA-mediated interference; S2, Schneider 2; EGFP, enhanced green fluorescent protein; MAP, mitogen-activated protein; ERK, extracellular signal-regulated kinase; MEK, MAP/ERK kinase; RT, reverse transcription.
| |
Footnotes |
|---|
* To whom reprint requests should be addressed. E-mail: marc.mumby{at}UTsouthwestern.edu.
| |
References |
|---|
|
|
|---|
| 1. |
Virshup, D. M.
(2000)
Curr. Opin. Cell Biol.
12,
180-185[CrossRef][ISI][Medline]
|
| 2. |
Janssens, V.
& Goris, J.
(2001)
Biochem. J.
353,
417-439[CrossRef][ISI][Medline]
|
| 3. |
Zhao, Y.
, Boguslawski, G.
, Zitomer, R. S.
& DePaoli-Roach, A. A.
(1997)
J. Biol. Chem.
272,
8256-8262 |
| 4. |
Kamibayashi, C.
, Estes, R.
, Lickteig, R. L.
, Yang, S.-I.
, Craft, C.
& Mumby, M. C.
(1994)
J. Biol. Chem.
269,
20139-20148 |
| 5. |
Haccard, O.
, Jessus, C.
, Cayla, X.
, Goris, J.
, Merlevede, W.
& Ozon, R.
(1990)
Eur. J. Biochem.
192,
633-642[ISI][Medline]
|
| 6. |
Moran, M. F.
, Koch, C. A.
, Anderson, D.
, Ellis, C.
, England, L.
, Martin, G. S.
& Pawson, T.
(1990)
Proc. Natl. Acad. Sci. USA
87,
8622-8626 |
| 7. |
Alessi, D. R.
, Gomez, N.
, Moorhead, G.
, Lewis, T.
, Keyse, S. M.
& Cohen, P.
(1995)
Curr. Biol.
5,
283-295[CrossRef][ISI][Medline]
|
| 8. |
Gause, K. C.
, Homma, M. K.
, Licciardi, K. A.
, Seger, R.
, Ahn, N. G.
, Peterson, M. J.
, Krebs, E. G.
& Meier, K. E.
(1993)
J. Biol. Chem.
268,
16124-16129 |
| 9. |
Sonoda, Y.
, Kasahara, T.
, Yamaguchi, Y.
, Kuno, K.
, Matsushima, K.
& Mukaida, N.
(1997)
J. Biol. Chem.
272,
15366-15372 |
| 10. |
Sontag, E.
, Fedorov, S.
, Kamibayashi, C.
, Robbins, D.
, Cobb, M.
& Mumby, M.
(1993)
Cell
75,
887-897[CrossRef][ISI][Medline]
|
| 11. |
Abraham, D.
, Podar, K.
, Pacher, M.
, Kubicek, M.
, Welzel, N.
, Hemmings, B. A.
, Dilworth, S. M.
, Mischak, H.
, Kolch, W.
& Baccarini, M.
(2000)
J. Biol. Chem.
275,
22300-22304 |
| 12. |
Sieburth, D. S.
, Sundaram, M.
, Howard, R. M.
& Han, M.
(1999)
Genes Dev.
13,
2562-2569 |
| 13. |
Wassarman, D. A.
, Solomon, N. M.
, Chang, H. C.
, Karim, F. D.
, Therrien, M.
& Rubin, G. M.
(1996)
Genes Dev.
10,
272-278 |
| 14. |
Jensen, P. H.
, Fladmark, K. E.
, Gjertsen, B. T.
& Vintermyr, O. K.
(1999)
Br. J. Cancer
79,
1685-1691 |
| 15. |
Rajesh, D.
, Schell, K.
& Verma, A. K.
(1999)
Mol. Pharmacol.
56,
515-525 |
| 16. |
von Zezschwitz, C.
, Vorwerk, H.
, Tergau, F.
& Steinfelder, H. J.
(1997)
FEBS Lett.
413,
147-151 |
| 17. |
Yan, Y.
, Shay, J. W.
, Wright, W. E.
& Mumby, M. C.
(1997)
J. Biol. Chem.
272,
15220-15226 |
| 18. |
Thiery, J. P.
, Blazsek, I.
, Legras, S.
, Marion, S.
, Reynes, M.
, Anjo, A.
, Adam, R.
& Misset, J. L.
(1999)
Hepatology
29,
1406-1417[Medline]
|
| 19. |
Lim, I. K.
, Park, T. J.
, Park, S. C.
, Yoon, G.
, Kwak, C. S.
, Le, M. S.
, Song, K. Y.
, Choi, Y. K.
& Hyun, B. H.
(2001)
Int. J. Cancer
91,
32-40[Medline]
|
| 20. |
Gjertsen, B. T.
& Doskeland, S. O.
(1995)
Biochim. Biophys. Acta
1269,
187-199 |
| 21. |
Ruvolo, P. P.
, Deng, X.
, Ito, T.
, Carr, B. K.
& May, W. S.
(1999)
J. Biol. Chem.
274,
20296-20300 |
| 22. |
Deng, X. M.
, Ito, T.
, Carr, B.
, Mumby, M.
& May, W. S.
(1998)
J. Biol. Chem.
273,
34157-34163 |
| 23. |
Santoro, M. F.
, Annand, R. R.
, Robertson, M. M.
, Peng, Y. W.
, Brady, M. J.
, Mankovich, J. A.
, Hackett, M. C.
, Ghayur, T.
, Walter, G.
, Wong, W. W.
,
et al.
(1998)
J. Biol. Chem.
273,
13119-13128 |
| 24. |
Kleinberger, T.
& Shenk, T.
(1993)
J. Virol.
67,
7556-7560 |
| 25. |
Shtrichman, R.
, Sharf, R.
, Barr, H.
, Dobner, T.
& Kleinberger, T.
(1999)
Proc. Natl. Acad. Sci. USA
96,
10080-10085 |
| 26. |
Shtrichman, R.
, Sharf, R.
& Kleinberger, T.
(2000)
Oncogene
19,
3757-3765[CrossRef][Medline]
|
| 27. |
Marcellus, R. C.
, Chan, H.
, Paquette, D.
, Thirlwell, S.
, Boivin, D.
& Branton, P. E.
(2000)
J. Virol.
74,
7869-7877 |
| 28. |
Clemens, J. C.
, Worby, C. A.
, Simonson-Leff, N.
, Muda, M.
, Maehama, T.
, Hemmings, B. A.
& Dixon, J. E.
(2000)
Proc. Natl. Acad. Sci. USA
97,
6499-6503 |
| 29. |
Caplen, N. J.
, Fleenor, J.
, Fire, A.
& Morgan, R. A.
(2000)
Gene
252,
95-105[CrossRef][ISI][Medline]
|
| 30. |
Fire, A.
(1999)
Trends Genet.
15,
358-363[CrossRef][ISI][Medline]
|
| 31. |
Hunter, C. P.
(1999)
Curr. Biol.
9,
R440-R442[CrossRef][ISI][Medline]
|
| 32. |
Carthew, R. W.
(2001)
Curr. Opin. Cell Biol.
13,
244-248[CrossRef][ISI][Medline]
|
| 33. |
Mayer-Jaekel, R. E.
, Baumgartner, S.
, Bilbe, G.
, Ohkura, H.
, Glover, D. M.
& Hemmings, B. A.
(1992)
Mol. Biol. Cell
3,
287-298[Abstract] |
| 34. |
Orgad, S.
, Brewis, N. D.
, Alphey, L.
, Axton, J. M.
, Dudai, Y.
& Cohen, P. T.
(1990)
FEBS Lett.
275,
44-48 |
| 35. |
Mayer-Jaekel, R. E.
, Ohkura, H.
, Gomes, R.
, Sunkel, C. E.
, Baumgartner, S.
, Hemmings, B. A.
& Glover, D. M.
(1993)
Cell
72,
621-633[CrossRef][ISI][Medline]
|
| 36. |
Berry, M.
& Gehring, W.
(2000)
EMBO J.
19,
2946-2957[CrossRef][Medline]
|
| 37. |
Helps, N. R.
, Brewis, N. D.
, Lineruth, K.
, Davis, T.
, Kaiser, K.
& Cohen, P. T.
(1998)
J. Cell Sci.
111, Part 10,
1331-1340[Abstract] |
| 38. |
Brown, L.
, Borthwick, E. B.
& Cohen, P. T.
(2000)
Biochim. Biophys. Acta
1492,
470-476 |
| 39. |
Chen, M. S.
, Silverstein, A. M.
, Pratt, W. B.
& Chinkers, M.
(1996)
J. Biol. Chem.
271,
32315-32320 |
| 40. |
Kloeker, S.
, Bryant, J. C.
, Strack, S.
, Colbran, R. J.
& Wadzinski, B. E.
(1997)
Biochem. J.
327,
481-486 |
| 41. |
Cohen, P.
, Holmes, C. F.
& Tsukitani, Y.
(1990)
Trends Biochem. Sci.
15,
98-102[CrossRef][ISI][Medline]
|
| 42. |
Brewis, N. D.
, Street, A. J.
, Prescott, A. R.
& Cohen, P. T. W.
(1993)
EMBO J.
12,
987-996[ISI][Medline]
|
| 43. |
Hastie, C. J.
& Cohen, P. T. W.
(1998)
FEBS Lett.
431,
357-361 |
| 44. |
Chen, M. X.
, McPartlin, A. E.
, Brown, L.
, Chen, Y. H.
, Barker, H. M.
& Cohen, P. T.
(1994)
EMBO J.
13,
4278-4290[Medline]
|
| 45. |
Baharians, Z.
& Schönthal, A. H.
(1998)
J. Biol. Chem.
273,
19019-19024 |
| 46. |
Umi, H.
, Imazu, M.
, Maeta, K.
, Tsukamoto, H.
, Azuma, K.
& Takeda, M.
(1988)
J. Biol. Chem.
263,
3752-3761 |
| 47. |
Kremmer, E.
, Ohst, K.
, Kiefer, J.
, Brewis, N.
& Walter, G.
(1997)
Mol. Cell Biol.
17,
1692-1701[Abstract] |
| 48. |
Biggs, W. H., III
& Zipursky, S. L.
(1992)
Proc. Natl. Acad. Sci. USA
89,
6295-6299 |
| 49. |
Shiomi, K.
, Takeichi, M.
, Nishida, Y.
, Nishi, Y.
& Uemura, T.
(1994)
Development (Cambridge, U.K.)
120,
1591-1599 |
| 50. |
Anderson, N. G.
, Maller, J. L.
, Tonks, N. K.
& Sturgill, T. W.
(1990)
Nature (London)
343,
651-653 |
| 51. |
Gomez, N.
& Cohen, P.
(1991)
Nature (London)
353,
170-173 |
| 52. |
Sontag, E.
, Sontag, J. M.
& Garcia, A.
(1997)
EMBO J.
16,
5662-5671[CrossRef][ISI][Medline]
|
| 53. |
Chen, P.
, Lee, P.
, Otto, L.
& Abrams, J.
(1996)
J. Biol. Chem.
271,
25735-25737 |
| 54. |
Mills, J. C.
, Lee, V. M.
& Pittman, R. N.
(1998)
J. Cell Sci.
111,
625-636[Abstract] |
| 55. |
Fladmark, K. E.
, Brustugun, O. T.
, Hovland, R.
, Boe, R.
, Gjertsen, B. T.
, Zhivotovsky, B.
& Doskeland, S. O.
(1999)
Cell Death Differ.
6,
1099-1108[CrossRef][Medline]
|
| 56. |
Yan, Y.
& Mumby, M. C.
(1999)
J. Biol. Chem.
274,
31917-31924 |
| 57. |
Kumar, S.
& Doumanis, J.
(2000)
Cell Death Differ.
7,
1039-1044[CrossRef][Medline]
|
| 58. |
Fraser, A. G.
, McCarthy, N. J.
& Evan, G. I.
(1997)
EMBO J.
16,
6192-6199[CrossRef][ISI][Medline]
|
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
Y. Li, H. Wei, T.-C. Hsieh, and D. C. Pallas Cdc55p-Mediated E4orf4 Growth Inhibition in Saccharomyces cerevisiae Is Mediated Only in Part via the Catalytic Subunit of Protein Phosphatase 2A J. Virol., April 1, 2008; 82(7): 3612 - 3623. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Junttila, S.-P. Li, and J. Westermarck Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival FASEB J, April 1, 2008; 22(4): 954 - 965. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Kuo, K.-Y. Huang, C.-H. Yang, Y.-S. Yang, W.-Y. Lee, and C.-W. Chiang Regulation of Phosphorylation of Thr-308 of Akt, Cell Proliferation, and Survival by the B55{alpha} Regulatory Subunit Targeting of the Protein Phosphatase 2A Holoenzyme to Akt J. Biol. Chem., January 25, 2008; 283(4): 1882 - 1892. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Forester, J. Maddox, J. V. Louis, J. Goris, and D. M. Virshup Control of mitotic exit by PP2A regulation of Cdc25C and Cdk1 PNAS, December 11, 2007; 104(50): 19867 - 19872. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Lee and D. C. Pallas Leucine Carboxyl Methyltransferase-1 Is Necessary for Normal Progression through Mitosis in Mammalian Cells J. Biol. Chem., October 19, 2007; 282(42): 30974 - 30984. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Longin, K. Zwaenepoel, J. V. Louis, S. Dilworth, J. Goris, and V. Janssens Selection of Protein Phosphatase 2A Regulatory Subunits Is Mediated by the C Terminus of the Catalytic Subunit J. Biol. Chem., September 14, 2007; 282(37): 26971 - 26980. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bhasin, S. R. Cunha, M. Mudannayake, M. S. Gigena, T. B. Rogers, and P. J. Mohler Molecular basis for PP2A regulatory subunit B56{alpha} targeting in cardiomyocytes Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H109 - H119. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Nazarenko, R. Schafer, and C. Sers Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells J. Cell Sci., April 15, 2007; 120(8): 1393 - 1404. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Rahman-Roblick, U. Johannes Roblick, U. Hellman, P. Conrotto, T. Liu, S. Becker, D. Hirschberg, H. Jornvall, G. Auer, and K. G. Wiman p53 targets identified by protein expression profiling PNAS, March 27, 2007; 104(13): 5401 - 5406. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Shi, Y.-J. Chiu, Y. Cho, T. A. Bullard, M. Sokabe, and K. Fujiwara Down-regulation of ERK but not MEK phosphorylation in cultured endothelial cells by repeated changes in cyclic stretch Cardiovasc Res, March 1, 2007; 73(4): 813 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Liu, A. M. Silverstein, H. Shu, B. Martinez, and M. C. Mumby A Functional Genomics Analysis of the B56 Isoforms of Drosophila Protein Phosphatase 2A Mol. Cell. Proteomics, February 1, 2007; 6(2): 319 - 332. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. D. Glaser, Y. O. Lukyanenko, Y. Wang, G. M. Wilson, and T. B. Rogers JNK activation decreases PP2A regulatory subunit B56{alpha} expression and mRNA stability and increases AUF1 expression in cardiomyocytes Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1183 - H1192. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Stefansson and D. L. Brautigan Protein Phosphatase 6 Subunit with Conserved Sit4-associated Protein Domain Targets I{kappa}B{epsilon} J. Biol. Chem., August 11, 2006; 281(32): 22624 - 22634. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. Ossum, T. Wulff, and E. K. Hoffmann Regulation of the mitogen-activated protein kinase p44 ERK activity during anoxia/recovery in rainbow trout hypodermal fibroblasts J. Exp. Biol., May 1, 2006; 209(9): 1765 - 1776. [Abstract] [Full Text] [PDF] |
||||